When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

Eli Lilly and Company ( NYSE:LLY ) will increase its dividend from last year's comparable payment on the 10th of ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $742.35 which represents a slight increase of $16.63 or 2.29% from the prior close of $725.72. The stock opened at $731.27 and ...